Evaluation of immune efficacy of Newcastle disease virus mRNA vaccine
10.16303/j.cnki.1005-4545.2025.03.06
- VernacularTitle:新城疫病毒HN-mRNA疫苗在SPF鸡中的攻毒保护效果评价
- Author:
Miaomiao CUI
1
;
Jiaxuan FENG
;
Jindou LI
;
Jiaxin DING
;
Chunhong GUO
;
Feng JIANG
;
Xiaolei LIU
;
Zhuang DING
Author Information
1. 吉林大学动物医学学院人畜共患传染病重症诊治全国重点实验室,吉林长春 130062
- Publication Type:Journal Article
- Keywords:
Newcastle diseas virus;
HN mRNA vaccine;
HI antibody;
evaluating effectiveness of protection against virus attacks
- From:
Chinese Journal of Veterinary Science
2025;45(3):436-442
- CountryChina
- Language:Chinese
-
Abstract:
SPF chickens were immunized with HN-mRNA vaccine by intramuscular injection.He-magglutination inhibition(HI)test,lymphocyte proliferation test,RT-qPCR and pathological sec-tions were used to evaluate the humoral and cellular immunity and protection against challenge in-duced by the candidate HN-mRNA vaccine.The results showed that 2.5,5.0,and 7.5 μg HN-mR-NA induced HI antibody antibodies in a dose-dependent manner.Among them,the Hi antibody in-duced by 7.5 μg HN-mRNA was slightly higher than that of the weak toxic vaccine(La Sota strain).In addition,in response to the stimulation of inactivated NDV virus,the proliferation and activation of lymphocytes in 2.5,5.0 and 7.5 μg HN-mRNA immunization groups and commercial vaccine group were observed.To further evaluate the antiviral protection provided by HN mRNA immunization,the 105 ELD50 NDV strong strain NA-1 was used to attack the 7.5 μg HN-mRNA immunised group and the commercial weakened vaccine(La Sota strain)and PBS groups using na-sal and ocular drops.The results showed that the survival rate of 7.5 μg HN-mRNA immunization group and commercial vaccine group was 100％,and these vaccines could protect tissues and or-gans from the damage caused by virus infection.At the same time,7.5 μg HN-mRNA and commer-cial vaccine could shorten the time of virus shedding in vitro and the viral load in vivo.This study provides a foundational framework for the clinical application of NDV HN mRNA candidate vac-cines and offers insights for the development of novel mRNA vaccines for poultry.
